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Abstract 
Background: A practical and up-to-date consensus among experts is paramount to 
further improve patient care in actinic keratosis (AK).  
Objectives: To develop a structured consensus statement on the diagnosis, 
classification and practical management of AK based on up-to-date information.  
Methods: A systematic review of AK clinical guidelines was conducted. This 
informed the preparation of a three-round Delphi procedure followed by a consensus 
meeting, which combined the opinions of 16 clinical experts from 13 countries, to 
construct a structured consensus statement and a treatment algorithm positioning 
daylight photodynamic therapy (dl-PDT) among other AK treatment options. 
Results: The systematic review found deficiencies in current guidelines with respect 
to new AK treatments such as ingenol mebutate and daylight photodynamic therapy. 
The Delphi panel established consensus statements across definition, diagnosis, 
classification and management of AK. While the diagnosis of AK essentially rests on 
the nature of lesions, treatment decisions are based on several clinical and non-clinical 
patient factors and diverse environmental attributes. Participants agreed on ranked 
treatment preferences for the management of AK, and on classifying AK in three 
clinical situations: isolated AK lesions requiring lesion-directed treatment; multiple 
lesions within a small field and multiple lesions within a large field, both requiring 
specific treatment approaches. Different AK treatment options were discussed for 
each clinical situation. 
Conclusions: The results provide practical recommendations for the treatment of AK, 
which are readily transferable to clinical practice, and incorporate the physician’s 
clinical judgement. The structured consensus statement positioned dl-PDT as a 
valuable option for patients with multiple AKs in small or large fields. 
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Introduction 
Actinic keratosis (AK) is mainly caused by chronic ultraviolet (UV) radiation 
exposure, and is characterised by scaly or keratotic erythematous lesions.1 Incidence 
increases with age and is highly dependent on individuals’ geographical locations and 
skin types, as well as behaviours regarding sun exposure.2 It is estimated that, in 
Australia, between 11% and 40% of white people older than 40 years have some form 
of AK.3 Besides the cosmetic burden associated with AK, there is the risk that lesions, 
regardless of their clinical grade, will progress to squamous cell carcinoma (SCC).4-6 
With global ageing, AK will increasingly become a focus for healthcare systems.7 
Although numerous scientific publications on AK exist, uncertainties remain 
regarding the definition of AK as pre-cancerous or in situ SCC and with respect to 
disease severity classification according to, for example, the Olsen grading system. 
Investigating these questions is among the aims of this study. The introduction of new 
treatments for AK has improved the standard of care for patients.8 However, many 
guidelines place an emphasis exclusively on clinical efficacy and safety, without 
accounting for practical issues. These include considerations such as: the required 
treatment duration, adherence of patients to overly complex treatment regimens, 
compliance of frail patients to treatments with side effects (such as pain and time-to-
healing), and uncertainty as to the exact lesion area to be treated.9,10 These issues must 
be taken into account by treatment guidelines to ensure maximal compliance and 
adherence in a largely elderly patient population, and ultimately to maximise clinical 
efficacy in daily practice. Guidelines must also be updated to reflect current clinical 
practice; although recent treatments such as ingenol mebutate are included in global 
AK management guidelines, daylight photodynamic therapy (dl-PDT) is unclearly 
positioned in AK treatment guidelines.11,12 Error! Reference source not found.Table 
Page 3 of 47
For Peer Review
  
 
 
- 4 - 
1 presents all AK treatments with their current approved clinical indications in the 
European Union. A practical and up-to-date consensus is necessary to further improve 
care in practice. 
>>Table 1: EMA approval status of ranked treatments for AKError! Reference 
source not found.<< 
This study aimed to develop a structured consensus among clinical experts for the 
definition and management of AK. A systematic review of clinical guidelines for the 
management of AK was conducted, the output of which helped structure a Delphi 
panel. A consensus meeting comprising the same participants was organised to 
finalise consensus statements, as illustrated in Figure 1Error! Reference source not 
found.. 
>>Error! Reference source not found.Figure 1. Workflow summary of the 
consensus development<< 
Materials and Methods 
For the systematic review, databases were searched for treatment guidelines and 
consensus statements for the management of AK, as shown in Table 2. Search terms 
for MEDLINE and EMBASE databases, respectively searched via Pubmed and Ovid 
are given in Appendix 1. Studies were critically assessed using the AGREE II-Global 
Rating Scale.13 The AGREE II assessment tool allows evaluation of guideline 
methodology, including: guideline development methods, presentation, completeness 
of reporting, recommendation quality, and overall quality. The quality assessment is 
presented in Appendix 2. The search was conducted on September 4th 2015 and no 
limitations were applied in terms of publication dates; however, superseded versions 
of treatment guidelines were excluded. 
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>>Table 2. Systematic literature review methodology and search results<< 
A Delphi panel was convened to outline a structured consensus among clinical experts 
on the definition and management of AK on the basis of the systematic literature 
review. 
The Delphi technique is a research method aiming to rigorously organise convergence 
of opinion from participants concerning real-world issues.14 It is an iterative process 
whereby a questionnaire is submitted in several rounds to selected experts. Each 
subsequent round is supported with a non-nominative qualitative summary of the 
previous round. Answers from participants are computed into a paragraph without 
mentioning which participants supported the statements to prevent clinical experts 
from influencing each other.15 Summaries were associated with a consensus level 
ranging from 1 to 10 (where 1 corresponded to the lowest and 10 corresponded to the 
highest level of consensus) to inform participants on the level of consensus achieved 
in the previous round.  
Questions relative to treatment preferences – treatments that participants considered to 
be the best for patients – and demographics, for which consensus was not sought, 
were submitted prior to the first Delphi round. These questions together constitute 
what is hereafter referred to as the one-off questionnaire; participants were asked to 
rank treatment options they considered most suitable for the management of isolated 
and multiple AK from a list of 16 options. Demographic questions included aspects 
relative to academic and medical contributions, and country of practice. 
The Delphi panel consisted of three rounds. The Delphi questionnaire was developed 
by a scientific committee comprising three expert participants on the basis of the 
systematic review of guidelines. It focused on issues where lack of consensus was 
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identified, i.e. AK definition/diagnosis and factors influencing AK treatment decision-
making. It also included a set of three clinical cases, represented in Figure 2Error! 
Reference source not found., Figure 3Error! Reference source not found. and 
Figure 4Error! Reference source not found., whereby participants were required to 
assess the nature of AK, list their preferred management options and express their 
view on the appropriateness of dl-PDT use. The latter question was included due to 
the absence of dl-PDT in existing guidelines, as demonstrated in the literature review. 
>>Figure 2. Photograph representing clinical case 1<< 
>>Figure 3. Photograph representing clinical case 2<< 
>>Figure 4. Photograph representing clinical case 3<< 
The one-off questionnaire and Delphi panel were communicated and collected via 
email, and included eight and 33 questions, respectively. Sixteen clinical experts were 
selected on the basis of their expertise on AK and their ability to constitute a 
worldwide panel, represented by: scientific contributions (peer-reviewed journal 
articles and conference keynotes), and/or clinical expertise in regards to high number 
of AK patients treated, and/or number of AK-related clinical trials they had 
participated in as investigator over the previous five years. 
A list of treatment options for the management of AK was developed from the outputs 
of the Delphi panel and the systematic review of treatment guidelines. This was 
presented to the Delphi panel participants during a consensus meeting, and a final 
treatment algorithm was produced upon agreement of the expert panel. 
Results 
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Systematic review of guidelines 
Searches identified 612 citations for screening via database and hand searches, and 
nine treatment guidelines or consensus statements published between 2007 and 2015 
were ultimately extracted (Table 2).11,12,16-22 A Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) diagram of the study flow is 
given in Appendix 3. 
Where stated, all guidelines agreed that UV exposure was the most important 
causative factor for AK. Accordingly, high sun protection factor (SPF) sunscreen was 
recommended as a preventative measure in several guidelines.11,16,18,22 Further UV-
avoidance behaviours recommended by guidelines included: minimising peak-time 
exposure to the sun (11.00 am to 3.00 pm), wearing of broad-brimmed hats outdoors, 
and avoidance of artificial tanning.11,22,23 
Within the reviewed guidelines, low consensus existed on the definition of the 
condition in terms of AK status as a cancer in situ or a pre-cancerous lesion. AK was 
described as a premalignant or pre-cancerous lesion in three guidelines.16,17,22 Other 
guidelines regarded AK as either in situ SCC, or as a form of early-stage SCC.12,18-21 
Guidelines showed consensus in stating that a substantial risk exists for an AK lesion 
to progress to invasive SCC. Several guidelines produced guidance on grading AK 
severity. The Olsen grading system, or Röwbert-Huber classification, for AKs was 
used in some guidelines,11,19 while others did not report specific guidance for 
assessing the severity of AK.12,16,17,21,22 
A full summary of treatment recommendations across the guidelines is given in 
Appendix 4. For the medical and procedural management of isolated AK, the 
strongest recommendations made, by way of the frequency and strength of 
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recommendation, were for: cryotherapy, curettage and conventional photodynamic 
therapy (c-PDT). The weakest recommendations were made for 5-FU and imiquimod. 
Recommendations relating to curettage were found to be contradictory across 
guidelines, with guidelines applying a strong recommendation, weak recommendation, 
or no stated recommendation; as such, no consensus conclusion could be made from 
this evidence. For the management of multiple AK lesions, the strongest 
recommendations were made for c-PDT and 5-FU, then imiquimod and ingenol 
mebutate. The weakest recommendations were made for cryotherapy and laser 
therapies.8,12,16-22 Results associated with cryotherapy are highly dependent on the 
physician’s experience and skills, hence the recommendation variations for 
cryotherapy.  
Critical assessment of the extracted guidelines was performed using the AGREE II 
guideline evaluation tool. Three guidelines scored perfectly 11,12,22 and there were no 
major methodological concerns for the remaining guidelines (see Appendix 2). 
However, reporting of strength of evidence was found to be incomplete in a minority 
of guidelines.17,20 The recent introduction of ingenol mebutate, imiquimod 3.75%, 5-
FU combined with salicylic acid, and dl-PDT also rendered all guidelines obsolete, as 
none fully reflected the full spectrum of currently-available treatments.8 Additionally, 
some guidelines identified in this review provided recommendations restricted to 
specific geographical areas.18,20 Some guidelines were also compromised by ignoring 
practicalities associated with treatment, including patient ability to comply with 
treatment, as well as the overall duration/complexity of the treatment cycle. Certain 
guidelines imposed an overly theoretical approach to treatment, such as proposing AK 
maximal treatable area thresholds of 25 cm2, which is not a realistic threshold in 
clinical practice as a cheek and forehead represent 100 to 150 cm2 and a bald scalp 
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extends over 200 cm2.17,18 Some guidelines also advised four-week treatment courses 
(e.g. 5-FU, 3.75% imiquimod),8 with likely physician follow-up visits afterwards: a 
prolonged treatment period which would likely prove difficult for some 
patients.11,12,16-22 Finally, specific management for immunosuppressed patients was 
not addressed in some treatment guidelines.16,22 
One-off questionnaire and Delphi panel 
Sixteen clinical experts with extensive experience on AK participated in the Delphi 
panel. Over the past five years, participants reported a median of, 75 AK patients seen 
on a monthly basis,  11 AK-related publications, 25 AK-related conference keynotes 
and four AK-related clinical trials where acting as research investigator, as detailed in  
Table 3. 
>> 
Table 3. Descriptive characteristics of actinic keratosis participating clinical 
experts<< 
Definition, diagnosis and grading of AK. A consensus could not be found on the 
definition of AK as either cancer in situ or pre-cancerous lesions throughout the two 
initial rounds of the Delphi panel (data not shown). A statement relative to the 
existence of a disease continuum from AK to invasive SCC led to a consensus. 
Table 4 displays consensus statements relative to the definition and diagnosis of AK. 
Although reservations were expressed regarding its optimality, participants agreed 
that the Olsen grading system was useful in clinical practice. On the clinical relevance 
of the number, size, and thickness of AK lesions, participants generally agreed that 
these were crucial criteria for evaluating the severity of AK, and agreed that the 
distribution of AK lesions was not an important factor when establishing a diagnosis. 
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Experts agreed that it is essential to distinguish isolated AK lesions from those 
occurring in small and large fields of actinic damage, in order to make appropriate 
treatment decisions. Although stating that it was an arbitrary figure participants 
reached the consensus that five AK lesions is an appropriate threshold to distinguish 
isolated AK (<5 lesions) from multiple AK (≥5 lesions) within a small field. Several 
treatments for AK are only indicated for the treatment of isolated lesions, small fields 
of actinic damage, and some others for large fields of actinic damage, as shown in 
Table 1Error! Reference source not found.. The site of lesions was considered to be 
of moderate relevance for the diagnosis of AK. Participants agreed that patients with 
multiple AK always display a field of actinic damage surrounding the lesions.  
>>Table 4. Summary of consensus statements relative to the diagnosis of AK<< 
Management of AK. Participants agreed that decisions for the treatment of AK were 
based on multiple attributes, namely: patient clinical and non-clinical factors, 
healthcare, environmental, and economic factors. Table 5 and Table 6 display the 
consensus statements relative to these factors and attributes upon which participants 
agreed. 
Although participants agreed that the diagnosis of AK is based on a clinical 
assessment, they agreed on the necessity to conduct biopsies for suspicious lesions, 
meaning any of (but not exclusive to): infiltrated, painful, inflamed, and/or 
hyperkeratotic. Efficacy of treatments was identified as a paramount factor 
influencing treatment decisions, regardless of the patient’s immunosuppression status.  
Participants also agreed that while age was not an important attribute for treatment 
decision-making, concern was raised regarding patient capacity to comply with self-
administered treatments when physical function is impaired. Achieving optimal 
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compliance, and therefore best treatment outcomes, should be among the main drivers 
of treatment decisions, in alignment with patients’ physical and mental capacity.  
Similar to patient-level economic capability and technology availability, specific 
attributes of healthcare systems influence treatment decisions across the world. This is 
due to varying healthcare situations and treatment/technology availability in standard 
practice across different countries.  
Participants agreed that the main motivation for physicians to initiate treatment for 
AK is the prevention of lesion progression to invasive SCC; it was considered that 
patients, although also concerned with cancer, have a strong preference for treating 
aesthetic and comfort impairments when seeking treatment for AK. 
As immunosuppressed patients are at greater risk of progression to invasive SCC, a 
consensus was determined on the necessity for immediate primary preventive 
measures and curative treatments. 
>> Table 5. Summary of lesion and patient factors influencing AK treatment 
decision << 
>> Table 6. Attributes influencing AK treatment decision and motivations for 
treatment initiation << 
Resulting from the one-off questionnaire, the preferred management option for the 
treatment of isolated AK lesions was cryotherapy with an average of rank 1 – 
although acknowledging the crucial influence of the physician’s ability and 
experience – followed by imiquimod and the newest combination of 5-fluorouracil 
(5FU) with salicylic acid (average rank of 4). The preferred treatment for multiple AK 
lesions was dl-PDT (average rank of 1). Ingenol mebutate and c-PDT were the next 
most-preferred treatments (average rank of 2 for both).  
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>> Table 7. Participants’ average ranking of preferred treatments of isolated and 
multiple AK (results from the one-off questionnaire) << 
The three clinical cases shown in Figure 2, Figure 3 and Figure 4 represent a priori a 
spectrum of AK severity with varying lesion thickness, i.e. respectively isolated 
lesions, multiple lesions in limited areas, and multiple lesions in large fields of actinic 
damage. Expert perception of clinical assessments, management decisions and 
appropriateness of treatment options, including dl-PDT for clinical cases 1, 2 and 3 
are reported in Table 8, which presents summaries alongside the consensus level from 
the third round of the Delphi panel.  
Participants ultimately established that clinical case 1 displayed isolated AK, grade 
I/II with uncertainty regarding field cancerisation. The participants’ preferred 
treatment was cryotherapy, with recognised risk of hypopigmentation being a 
practical issue. 
Consensus was found to describe clinical case 2 as multiple AK, grades I, II and III in 
an area of field cancerisation. Participants agreed on the need to consider biopsy for 
the thicker lesion and field preparation to remove hyperkeratosis before field 
treatment, after which c-PDT would be preferred, followed by dl-PDT or 5-FU. Here, 
dl-PDT was considered appropriate for the treatment of the thinner lesions.  
Participants agreed that clinical case 3 displayed multiple AK lesions, grades I/II and 
an area of field cancerisation. Field treatment would be required, with a participants 
preferring using dl-PDT, followed by c-PDT, imiquimod and 5-FU. 
>> Table 8. Findings for the assessment, treatment and use of daylight PDT for 
clinical cases 1, 2 and 3 << 
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List of treatment options 
Figure 5Error! Reference source not found. shows the list of treatment options 
finalised at the consensus meeting of panel participants. Considering the number of 
significant factors and attributes influencing treatment decisions including clinical 
data, efficacy, safety, tolerability, labels, and clinical experience, different treatment 
options were considered for the different clinical situations. For example, dl-PDT was 
rated as a preferred option for patients with multiple AK on both small and large 
fields due to its efficacy and tolerability profile. Ingenol mebutate was rated as a 
valuable option for isolated AK lesions and multiple AK lesions on small fields due to 
its surface limitation per label, as well as its tolerability profile. Imiquimod 5% was 
rated as valuable option for the same profiles due to its tolerability profile, whereas 
Imiquimod 3.75% was rated as valuable option for multiple AK on large field as per 
its label. This Delphi panel therefore provides an outline of treatment factors to 
consider when physicians assess their own clinical cases.  
On the basis of management preferences expressed by participants, a distinction was 
made for the management of multiple lesions and fields of actinic damage, which 
were further divided between small and large fields of actinic damage. Although 
intentionally left ill defined, as the limitation of 25cm2 for some approved treatments 
is not realistic in clinical practice, the distinction between small and large fields of 
actinic damage allows treatment of restricted zones (e.g. nose, one cheek or part of 
forehead) or entire body areas (e.g. full scalp or full face). It was also decided to 
include specific recommendations for immunocompromised patients on the basis of 
the Delphi panel findings and further discussions during the consensus meeting. 
>>Error! Reference source not found.Figure 5. Treatment algorithm for the 
management of actinic keratosis<< 
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Discussion 
This study reports the findings of a systematic review of clinical guidelines for AK, 
and how the results have been used, in conjunction with an evolving consensus among 
clinical experts, to develop both consensus statements and a treatment algorithm. The 
treatment algorithm accounts for recent treatments and reflects on the limitations of 
past guidelines. Participants agreed on a treatment algorithm for the management of 
isolated and multiple AK, distinguishing lesion-directed treatment, small and large 
fields of actinic damage. Participants to the panel have agreed that isolated lesions 
should be removed with lesion directed treatments whereas multiple lesions should be 
treated differently if they spread over small or large fields. This is due to some 
treatment being approved only for smaller areas. Treating larger surfaces with 
treatments approved for smaller areas would require the physician to repeat 
consecutive cycles on adjacent areas, which can lead to an unacceptable overall 
treatment duration, increase the extent of treatment side effects and incur a strong 
increase of direct and indirect costs. This study reflects current preferences of experts 
on management of AK and reports dl-PDT, c-PDT, ingenol mebutate and imiquimod 
as preferred field treatments. This study’s outcome is also supported by recent 
findings showing that dl-PDT has a superior tolerability profile and is more 
cosmetically acceptable and preferred by patients 24. Considerations were made when 
detailing attributes and factors influencing treatment decision-making, ranging from 
the patient’s characteristics of AK lesions to the availability of technologies in 
practice.  
In addition, clinical experts with extensive experience of AK management have 
highlighted a number of practical issues to be considered when treating AK. The 
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consensus recommendations made are current and easily translatable to clinical 
practice. 
The current study is a structured consensus, and should not be considered a treatment 
guideline. This avoids the rigidity and limitations of guidelines, while providing 
methodologically aggregated opinions of worldwide renowned experts in the field of 
AK. Importantly, the consensus statement offers practical recommendations, allowing 
physicians to use their clinical judgement on each patient case. Furthermore, 
considering the limited long-term experience and knowledge on AK, a structured 
consensus rests among the most useful available evidence for treatment decisions at 
this point.  
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Tables 
Table 1: EMA approval status of ranked treatments for AK 
 
Treatment Indication 
c-PDT/dl-PDT 
MAL (Metvix®)25 
Treatment of thin or non-hyperkeratotic and non-pigmented 
AK on the face and scalp when other therapies are 
considered less appropriate. 
Imiquimod 3.75% 
(Zyclara®)26 
Clinically typical, non-hyperkeratotic, non-hypertrophic, 
visible or palpable AK of the full face or balding scalp in 
immunocompetent adults when other topical treatment 
options are contraindicated or less appropriate. 
Imiquimod 5% 
(Aldara®)27 
Clinically typical, non-hyperkeratotic, non-hypertrophic AK 
on the face or scalp in immunocompetent adult patients when 
size or number of lesions limit the efficacy and/or 
acceptability of cryotherapy and other topical treatment 
options are contraindicated or less appropriate. 
Ingenol mebutate 
(Picato®)28 
Ingenol mebutate is indicated for the cutaneous treatment of 
non-hyperkeratotic, non-hypertrophic actinic keratosis in 
adults. The content of one tube should be used for one 
treatment area of 25 cm2. 
5-FU + salicylic 
acid 
Treatment of AK. Response can be seen as early as in six 
weeks. Response increases over time and data are available 
for treatment up to 12 weeks. Complete healing of the 
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(Actikerall®)29 lesion(s) or optimal therapeutic effect may not be evident for 
up to eight weeks after treatment cessation.  
5-FU (topical) 
(Efudix®)30 
Treatment of AK. The cream should be applied thinly to the 
affected area once or twice daily; an occlusive dressing is not 
essential. 
Diclofenac/ 
hyaluronate 
(Solaraze®)31 
Treatment of AK. The amount needed depends on the size of 
the lesion. Usual duration of therapy: 60 to 90 days. 
Maximum efficacy has been observed with treatment 
duration towards the upper end of this range.  
Complete healing of the lesion(s) or optimal therapeutic 
effect may not be evident for up to 30 days following 
cessation of therapy. Long term efficacy not established. 
c-PDT ALA 
(Ameluz®)32  
Treatment of AK of mild to moderate intensity on the face 
and scalp (Olsen grade 1 to 2) 
AK: actinic keratosis; c-PDT: conventional photodynamic therapy; dl-PDT: daylight 
photodynamic therapy; MAL: Methyl aminolevulinate; ALA: 5-aminolaevulinic acid  
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Table 2. Systematic literature review methodology and search results 
 
Search details  
Databases searched 
MEDLINE 
MEDLINE-in-Process 
EMBASE 
Limits 
Population: Patients with AK 
Intervention: No restriction 
Comparator: No restriction 
Outcomes: Multi-treatment recommendations for 
management of actinic keratosis 
Study Type: Clinical guidelines from recognised 
large organisations, consensus statements 
Hand searches 
Dermatology organisations, relevant conference 
abstracts/posters (from 2012) 
Inclusion criteria 
Conference abstracts of interest: published 2012 – 
2015 
Study type of interest: Treatment guideline or 
recommendation 
Population of interest: Patients with AK 
Outcome of interest: Recommendations for the 
management of AK 
Locations of interest: EU, Latin America, 
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Australia, Canada 
Exclusion criteria 
Duplicate, not in the language of interest (English), 
abstract that is reported elsewhere 
Search results 
Number of references 
identified through the 
systematic literature searches 
n = 609 
Number of references 
identified through the hand 
searches 
n = 3 
Number of articles included 
in the systematic review 
n = 9 
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Table 3. Descriptive characteristics of actinic keratosis participating clinical 
experts 
Countries of practice 
Two each from: 
Germany, Italy, Canada 
One each from: France, 
Netherlands, Denmark, 
UK, Spain, Greece, 
Mexico, Brazil, 
Argentina, Australia 
Average monthly number of AK patients seen (range 
(median)) 
20-400 (75)  
Number of AK-related peer-reviewed journal articles in 
the last 5 years (range (median)) 
0-22 (11) 
Number of AK-related conference keynotes in the last 5 
years (range (median)) 
0-50 (25) 
Number of AK-related clinical trials where acting as 
investigator in the last 5 years (range (median)) 
0-20 (4) 
AK: actinic keratosis; UK: United Kingdom 
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Table 4. Summary of consensus statements relative to the diagnosis of AK 
Legend: computed summaries of the third iteration of the Delphi panel on questions 
relative to the diagnosis of AK. 
Topic Consensus statement 
AK: cancer in situ or 
pre-cancerous 
lesions? 
Regardless of lesion thickness, there is a disease continuum 
extending from AK to invasive SCC. 
Olsen grading: 
appropriate for AK 
diagnosis? 
Although it could be improved, the Olsen grading system is 
appropriate mainly because it is currently a standard used in 
practice and in clinical trials for diagnosis and prognosis. It 
is a useful tool in clinical practice. Using a thin/thick grading 
system may also be useful. 
Number of lesions 
differentiate isolated 
and multiple AK 
Although it is an arbitrary threshold, isolated AK is 
represented by less than five AK lesions, while multiple AK 
is represented by five AK lesions or more. This threshold is 
not fixed and other factors such as the size of the AKs and 
surrounding skin photo damage may modify the diagnosis. 
The number of lesions is of paramount importance to 
clinically describe the severity of AK. It is the number one 
criterion to assess the severity of AK. However, it is not the 
only criterion and needs to be combined with lesion size and 
thickness. 
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Lesion size and 
thickness  
The thickness of lesions is at least as important as the 
number of lesions for diagnosis. The size of lesions is a 
crucial criterion for the clinical definition of AK, although of 
less importance than the number of lesions.  
Surrounding skin 
and field of actinic 
damage 
In a patient with multiple AK, it is very likely that 
surrounding skin harbours a field of actinic damage as a 
similar sun exposure has been sustained. 
Lesion distribution The distribution of lesions as a characteristic for the clinical 
assessment of AK is moderately relevant to AK diagnosis. 
AK, actinic keratosis; SCC, squamous cell carcinoma.  
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Table 5. Summary of lesion and patient factors influencing AK treatment 
decision. 
Legend: computed summaries of the third iteration of the Delphi panel on questions 
relative to patient factors influencing AK treatment decisions. 
Topic Consensus statement 
Lesion nature Lesion number and thickness are the most important criteria 
(see previous table). The size of lesions is also to be 
considered for treatment decision. Thicker and/or larger 
lesions may require a biopsy and prior intervention before 
treatment initiation and more careful follow-up. Treatment of 
the surrounding actinic damage may be necessary. Lesion 
distribution can be important when choosing treatments: hard 
to reach locations for application may require the help of 
caregivers. 
Immunosuppression 
status 
The immunosuppression status of a patient strongly 
influences treatment decisions. It influences other AK 
characteristics such as the number and invasiveness potential 
of lesions. Immunosuppressed patients must be managed 
more carefully as they are at greater risk of invasive SCC: 
treatment choices are different as treatment safety and 
efficacy vary and knowledge is sometimes scarce in this 
population subgroup. Sun protection is key to prevent new 
lesions in immunosuppressed patients. 
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Patient treatment 
history 
Patient's treatment history and their treatment preferences are 
important attributes for treatment decision-making, to ensure 
maximal adherence and optimal treatment outcomes. 
Other patient 
clinical attributes 
Several other attributes influence treatment decisions, 
including time to healing; patient's AK/SCC history plays a 
role in management decisions 
Patient 
characteristics 
Patient’s age is generally not an important attribute in 
treatment decisions. However, the patient's capacity to 
comply with treatments matters. This includes health aspects 
such as the understanding of the treatment modality, the 
manual ability to manage treatments by him/her-self and 
dependency or presence of family or professional caregivers. 
Although this can never be taken for granted, older people 
have a lesser focus on cosmetic aspects of the condition. This 
patient preference may influence treatment choices. 
The relevance of patients' economic status as an attribute for 
prescribing specific treatments varies according to countries' 
healthcare settings. 
PDT, photodynamic therapy; AK, actinic keratosis; SCC, squamous cell carcinoma. 
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Table 6. Attributes influencing AK treatment decision and motivations for 
treatment initiation 
Legend: computed summaries of the third iteration of the Delphi panel on questions 
relative to attributes not related to patients influencing treatment decisions and 
motivations for treatment initiation. 
Topic Consensus statement 
Time Time is an important attribute for treatment choices. Doctors 
seek optimal patient treatment compliance. Hence, treatment 
duration and regimen do influence treatment decisions.  
Medical results The importance of medical results in treatment choices is 
paramount, firstly regarding efficacy but also safety. The 
existence (or absence) of high quality scientific evidence also 
drives treatment choices. 
Availability of 
technology 
The availability of technologies only influences treatment 
decisions in settings where not all devices/treatments are 
available.  
Economic 
attributes 
Economic attributes have a significant impact on prescribing. 
Treatments are not always reimbursed, either by private or 
public insurance. Some treatments are not approved for AK 
III. Costs to the healthcare system rarely influence prescribing 
decisions. In some settings hospitalisation is a way to gain 
healthcare coverage for certain treatments. 
As an example, requirements for daylight exposure with dl-
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PDT introduce a seasonal and geographic component in some 
markets, which influences treatment decisions. 
Motivations for 
treatment initiation 
The main motivation of doctors to treat AK is the prevention 
of the progress of lesions to SCC. Patient motivations for 
initiating AK treatment mainly include (order varies) 
aesthetics, pain/discomfort and fear of developing/having skin 
cancer.  
AK, actinic keratosis; PDT: photodynamic therapy; dl-PDT: daylight photodynamic 
therapy; SCC, squamous cell carcinoma.  
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Table 7. Participants’ average ranking of preferred treatments of isolated and 
multiple AK (results from the one-off questionnaire) 
Legend: Average ranking for each management option for isolated and multiple AK 
provided by participants in the one-off questionnaire. Exact question asked: ‘In your 
practice, can you rank treatments for isolated/multiple AK that you consider to be the 
best for your patients (best (1) to worst (16))? You may use the same number several 
times if you wish.’ 
Isolated lesions
1
 Multiple lesions
1
  
Cryotherapy 1 Dl-PDT 1 
Imiquimod2 4 Ingenol mebutate 2 
5-FU + salicylic acid. 4 C-PDT 2 
5-FU 5 Imiquimod2 3 
Ingenol mebutate 5 5-FU  3 
Curettage 5 Diclofenac/hyaluronate 
(top.) 
6 
C-PDT 5 5-FU + salicylic acid. 8 
Dl-PDT 6 Laser resurfacing 9 
Excision 9 Cryotherapy 10 
Diclofenac/hyaluronate (top.) 10 Chemical peels  10 
Ablative CO2 laser 11 Curettage 11 
Surveillance 13 Dermabrasion 11 
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Dermabrasion 15 Excision 15 
Chemical peels  15 Surveillance 15 
DNA repair enzymes  15 Nothing  16 
Nothing  16 DNA repair enzymes  16 
5-FU: 5-fluorouracil; top.: topical; c-PDT: conventional photodynamic therapy; dl-
PDT: daylight photodynamic therapy.  
1 In the early stages, the study did not consider small or large fields of actinic damage. 
2 In the early stages of the study, imiquimod 5% and 3.75% were not differentiated. 
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Table 8. Findings for the assessment, treatment and use of daylight PDT for 
clinical cases 1, 2 and 3 
Legend: Results from each of the three iterations of the Delphi panel relative to the 
assessment, treatment preferences and appropriateness of use of dl-PDT for clinical 
case 1, 2 and 3. Exact questions asked: ‘The following three questions are clinical 
cases. On the basis of the following pictures, please assess the clinical features of AK 
and the most appropriate treatment to provide. Please assume that patients are not 
immunocompromised. (1) Clinical assessment of clinical case 1/2/3. (2) What are the 
most appropriate treatments for clinical case 1/2/3? (3) Is daylight PDT relevant for 
clinical case 1/2/3?’ 
 
Assessment Treatment Dl-PDT use 
Clinical 
case 1 – 
round 3 
Isolated AK, 
grades I/II 
with 
uncertainty 
regarding 
field 
cancerisation.  
(CL: 10) 
Although there is a 
risk of 
hypopigmentation, 
cryotherapy is among 
the first treatment 
options. Then (order 
varies) c-PDT, 
imiquimod or 5-FU, 
ingenol mebutate  
(CL: 8) 
Dl-PDT (most often to the 
whole face) is more 
appropriate when multiple 
AK and/or suspecting a 
cancerisation field. In the 
case of single lesions, more 
practical alternatives are 
preferable. Reimbursement 
status may affect the use of 
dl-PDT.  
(CL: 9) 
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Clinical 
case 2 – 
round 3 
Multiple AK 
grades I, II 
and III in an 
area of field 
cancerisation.  
(CL: 10) 
Biopsy is considered 
for thick lesions. Prior 
to treatment, field 
preparation using 
curettage is required. 
First option for 
treatment is c-PDT, 
then (order varies) dl-
PDT, or 5-FU. Last 
Imiquimod and 
Ingenol Mebutate may 
be used.  
(CL: 9) 
Dl-PDT is appropriate for the 
thinner lesions. Thicker 
lesions must be treated 
separately and prior to dl-
PDT.  
(CL: 10) 
Clinical 
case 3 – 
round 3 
Multiple AK, 
Grade I/II 
and field 
cancerisation.  
(CL: 10) 
Field treatment is 
required, with 
preferably dl-PDT but 
also c-PDT, 
Imiquimod, 5-FU.  
(CL: 9) 
Yes. This choice may depend 
on dl-PDT reimbursement 
status and sun exposure 
(season/location).  
(CL: 10) 
c-PDT: conventional photodynamic therapy; dl-PDT: daylight photodynamic therapy; 
AK, actinic keratosis; CL: consensus level; 5-FU: 5-fluorouracil.  
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Figures 
Figure 1. Workflow summary of the consensus development 
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Figure 2. Photograph representing clinical case 1 
 
Source: DermQuest.com 
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Figure 3. Photograph representing clinical case 2 
 
Source: DermQuest.com 
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Figure 4. Photograph representing clinical case 3 
 
 
Source: Department of Dermatology, University of Brescia, Brescia, Italy 
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Figure 5. Treatment algorithm for the management of actinic keratosis 
 
PDT, photodynamic therapy; AK, actinic keratosis. 
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Appendix 1: Search terms for the systematic review of clinical guidelines 
 
MEDLINE and MEDLINE-in-Process via Pubmed 
# Search terms 
1 keratosis, actinic[mh] OR (actinic[tiab] AND keratos*[tiab]) OR (Solar[tiab] 
AND keratos*[tiab]) OR (senile[TIAB] AND keratos*[TIAB]) OR 
hyperkeratos*[TIAB] 
2 guideline[PT] 
3 Clinical pathway[mh] OR Clinical protocol[mh] OR Consensus[mh] OR 
Consensus development conferences as topic[mh]  
4 Critical pathways[mh] OR Guidelines as topic [Mesh:NoExp] OR Practice 
guidelines as topic[mh] OR Health planning guidelines[mh] OR guideline[pt] 
OR practice guideline[pt] 
5 consensus development conference[pt] OR consensus development 
conference, NIH[pt] OR position statement*[tiab] OR policy statement*[tiab]  
6 practice parameter*[tiab] OR best practice*[tiab] OR standards[ti] OR 
guideline[ti] OR guidelines[ti] OR ((practice[tiab] OR treatment*[tiab]) 
AND guideline*[tiab]) 
7 CPG[tiab] OR CPGs[tiab] OR consensus*[tiab] OR ((critical[tiab] OR 
clinical[tiab] OR practice[tiab]) AND (path[tiab] OR paths[tiab] OR 
pathway[tiab] OR pathways[tiab] OR protocol*[tiab]))  
8 recommendat*[ti] OR (care[tiab] AND (standard[tiab] OR path[tiab] OR 
paths[tiab] OR pathway[tiab] OR pathways[tiab] OR map[tiab] OR 
maps[tiab] OR plan[tiab] OR plans[tiab])) 
9 (algorithm*[tiab] AND (screening[tiab] OR examination[tiab] OR test[tiab] 
OR tested[tiab] OR testing[tiab] OR assessment*[tiab] OR diagnosis[tiab] 
OR diagnoses[tiab] OR diagnosed[tiab] OR diagnosing[tiab])) OR 
(algorithm*[tiab] AND (pharmacotherap*[tiab] OR chemotherap*[tiab] OR 
chemotreatment*[tiab] OR therap*[tiab] OR treatment*[tiab] OR 
intervention*[tiab])) 
10 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
11 #1 AND #10 
 
EMBASE via Ovid 
# Search terms 
1 actinic keratos$.mp. or exp Keratosis, Actinic/ OR solar keratos$.mp. OR 
senile keratos$.mp. OR hyperkeratos$.mp 
2 exp clinical pathway/ 
3 exp clinical protocol/ 
4 exp consensus/ 
5 exp consensus development conference/ 
6 exp consensus development conferences as topic/ 
7 critical pathways/ 
8 exp guidelines/ 
9 guidelines as topic/ 
10 exp practice guideline/ 
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11 practice guidelines as topic/ 
12 health planning guidelines/ 
13 treatment guidelines.mp. 
14 (guideline or practice guideline or consensus development conference or 
consensus development conference, NIH).pt. 
15 (position statement* or policy statement* or practice parameter* or best 
practice*).ti,ab. 
16 (standards or guideline or guidelines).ti. 
17 ((practice or treatment*) adj guideline*).ab. 
18 (CPG or CPGs).ti. 
19 consensus*.ti. 
20 consensus*.ab. /freq=2 
21 ((critical or clinical or practice) adj2 (path or paths or pathway or pathways 
or protocol*)).ti,ab. 
22 recommendat*.ti. 
23 (care adj2 (standard or path or paths or pathway or pathways or map or maps 
or plan or plans)).ti,ab. 
24 (algorithm* adj2 (screening or examination or test or tested or testing or 
assessment* or diagnosis or diagnoses or diagnosed or diagnosing)).ti,ab. 
25 (algorithm* adj2 (pharmacotherap* or chemotherap* or chemotreatment* or 
therap* or treatment* or intervention*)).ti,ab. 
26 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR 
#12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 Or #20 OR 
#21 OR #22 OR #23 OR #24 OR #25 
27 #1 AND #26 
 
 
 
 
Page 37 of 47
For Peer Review
  
 
 
- 38 - 
 
Appendix 2: Quality assessment – AGREE II-Global Rating Scale 
 
Title Author(s) Rate the overall 
quality of the 
guideline 
development 
methods 
Rate the overall 
quality of the 
guideline 
presentation 
Rate the 
completeness of 
reporting. 
Rate the overall 
quality of the 
guideline 
recommendations 
Rate the 
overall 
quality of 
the 
guideline 
Guidelines for the 
management of actinic 
keratoses 
De Berker 
et al. 
7 7 6 6 6 
Management of actinic 
keratosis: a practical 
report and treatment 
algorithm from 
AKTeam expert 
clinicians 
Dreno 
B.;Amici J 
et al. 
6 6 7 7 6 
Spanish adaptation of 
the European guidelines 
for the evaluation and 
treatment of actinic 
keratosis 
Ferrándiz C 
et al. 
4 7 7 7 7 
Swiss clinical practice 
guidelines on field 
cancerization of the skin 
Hofbauer G 
et al. 
6 6 7 7 6 
Key Opinion Leader 
(KOL) consensus for 
Peserico A  4 6 5 4 5 
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Title Author(s) Rate the overall 
quality of the 
guideline 
development 
methods 
Rate the overall 
quality of the 
guideline 
presentation 
Rate the 
completeness of 
reporting. 
Rate the overall 
quality of the 
guideline 
recommendations 
Rate the 
overall 
quality of 
the 
guideline 
actinic keratosis 
management in Italy: 
The AKTUAL 
Workshop 
et al. 
Development of a 
treatment algorithm for 
actinic keratoses: A 
European Consensus 
Stockfleth 
E et al. 
6 7 7 7 7 
Guidelines for the 
diagnosis and treatment 
of cutaneous squamous 
cell carcinoma and 
precursor lesions 
J.J. 
Bonerandi 
et al.  
7 7 7 7 7 
Non-melanoma Skin 
Cancer in Canada 
Chapter 3: Management 
of Actinic Keratoses 
Poulin Y et 
al. 
7 7 7 7 7 
Evidence- and 
consensus-based (S3) 
Guidelines for the 
Treatment of Actinic 
Keratosis 
R.N. 
Werner et 
al. 
7 7 7 7 7 
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Quality is rated from 1 (worst) to 7 (best) 
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Appendix 3: PRISMA diagram for systematic review of clinical guidelines 
 
 
Page 41 of 47
For Peer Review
  
 
 
- 42 - 
Appendix 4: Summary of recommendations for the management of actinic keratosis 
Legend: Table representing recommendations for the management of AK as reported in publications included in the systematic review of clinical 
guidelines. 
  No therapy Emollient Salicylic 
acid 
5-FU Diclofenac  Imiquimod 5% Ingenol 
mebutate 
Topical 
retinoids 
Systemic 
retinoids 
De Berker 
2006
a
 
A, II-ii A, I A, III A, I B, I B, I       
Dreno 2014
b
     1st line 1st line 1st line 1st line 1st line     
Ferrándiz 
2014
c
 
    2 (with 5-
FU) 
2 2 2 2   3 
Hofbauer 
2014
d
 
      FD, 1 FD, 1 FD, 1 FD, 1 FD, 2   
Peserico 
2013
e
 
Sunblock: 
0.01, 0.02 
      1.21 1.71       
2.22 2.72 
Stockfleth 
2008
f
 
      50% 50-79% 55-84%     0-85% 
Bonerandi 
2011
g
 
      1, LOE1   1, LOE1       
Poulin 
2015
h
 
      S: Weak 
(mod.) 
  S: Strong (high) S: Strong 
(high) 
    
M: Weak 
(low) 
M: Strong 
(high) 
M: Strong 
(high) 
Werner 
2015
i
 
    S: ↑ (with 
5-FU) 
S: ↑ S: 0 S: ↑ M: ↑↑     
M: ↑↑ M: ↑ M: ↑↑ 
(imiquimod 
3.75%) 
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  PDT Cryosurgery Curettage Excision Laser Chemical 
peeling 
Dermabrasion Radiotherapy 
De Berker 
2006
a
 
B, I A, I     C, III C, III C, III   
Dreno 2014
b
 1st line 1st/2nd line 1st/2nd line   1st line   1st line   
Ferrándiz 
2014
c
 
2 1 1   1 (CO2) 3 3   
Hofbauer 
2014
d
 
FD/LD, 3 
(ALA, 
MAL) 
  LD, 4 LD (N/A) FD, 3 FD, 3 FD, 4 FD, 4 
Peserico 
2013
e
 
2.81, 4.82 3.81, 1.72 0.51, 0.32 3.21, 1.02 CO2: 3.0
1, 
1.32 
0.51, 0.22     
Erbium: 
0.31, 1.02 
Stockfleth 
2008
f
 
70-90% # 75-98% Undocumented Undocumented ~90% ~75%     
Bonerandi 
2011
g
 
1, LOE2 1             
Poulin 
2015
h
 
M: Strong 
(high) 
S: Strong 
(mod.) 
S: Strong 
(mod.) 
S: Strong 
(mod.) 
M: Low 
(weak) 
M: Low 
(weak) 
    
Werner 
2015
i
 
S: ↑ S: ↑↑ S: ↑   S: 0       
M: ↑↑ M: ↑ M: 0 M: ↑ 
 
a Strength of recommendation rated from A (best) to E (worst) and quality of evidence rated from I (best) to IV (worst) 
b Therapies recommended for: 1: first line treatment for non-hyperkeratotic or hyperkeratotic isolated/multiple AK, or 1*: first line treatment of 
isolated/small numbers of AK and second line treatment in cases of recurrence 
c Recommendations were made according to the following treatment aims: 1: Destructive therapies should be applied to solitary AKs or 
whenever invasive SCC is suspected. 2: Topical treatments are preferable to destructive ones in patients with multiple AKs or evident field 
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cancerization because topical formulations treat both the visible lesions and the field. 3: Orally administered systemic retinoids, dermabrasion, 
chemical peelings, and CO2 laser treatments are second-line or coadjutant therapies. They should be considered for use in special circumstances. 
d Therapies recommended for lesion-directed (LD) or field-directed (FD) treatment. Level of evidence reported according to OCEBM 
e Treatment options for 1: isolated AK, or 2: multiple AK/filed cancerisation, were ranked according to consensus (1 = completely disagreed - 5 = 
completely agreed) 
f Treatments were evaluated according to response rate, #: response rates enhanced by curettage 
g First-line therapies for isolated/multiple AK are presented 
h Strength of recommendation (and level of evidence) given for single (S) or multiple (M) AKs 
i Recommendations for single (S) or multiple (M) AKs. ↑↑: Strong recommendation; ↑: Weak recommendation; 0: No recommendation 
AK: Actinic keratosis; FD: Field-directed; LD: Lesion-directed; LOE: Level of evidence; OCEBM: Oxford Centre for Evidence Based Medicine; 
M: Multiple AK; Mod.: Moderate; S: Single AK; SCC: Squamous cell carcinoma 
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